Fernanda Cooley, APRN
Psychiatric/Mental Health · Tulsa, OKNPI 1235656216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 415 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,058, 4.0 times the $1,265 reported in 2021. Among psychiatric/mental health clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $37.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Alkermes, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- plus $5K from 13 others
What the payments were for
- Food & beverage$15,24698%
- Education$2702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 57 | $2,807 |
| Alkermes, Inc. | 59 | $1,961 |
| Neurocrine Biosciences, Inc. | 48 | $1,816 |
| Teva Pharmaceuticals USA, Inc. | 30 | $1,248 |
| Otsuka America Pharmaceutical, Inc. | 35 | $1,165 |
| AbbVie | 29 | $1,104 |
| Vanda Pharmaceuticals Inc. | 23 | $1,093 |
| Axsome Therapeutics, Inc. | 23 | $1,088 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $1,001 |
| Indivior Inc. | 43 | $753 |
| E.r. Squibb & Sons, L.L.C. | 24 | $562 |
| Supernus Pharmaceuticals, Inc. | 2 | $249 |
| Pear Therapeutics (US), Inc. | 2 | $167 |
| Lundbeck LLC | 8 | $131 |
| Corium, LLC | 1 | $123 |
| Idorsia Pharmaceuticals US Inc | 1 | $115 |
| Noven Therapeutics, LLC | 3 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $47 |
| Boehringer Ingelheim | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,624
- INVEGA SUSTENNA$1,139
- INGREZZA$959
- SPRAVATO$858
- VRAYLAR$838
- INVEGA TRINZA$664
- Fanapt$599
- CAPLYTA$505
- Auvelity$473
- ARISTADA$423
- REXULTI$380
- QELBREE$249
- Austedo XR$241
- VIVITROL$238
- UZEDY$234
- AUSTEDO$131
- Azstarys$123
- ABILIFY ASIMTUFII$123
- ABILIFY MAINTENA$123
- COBENFY$122
How this compares
$15,516 in reported general payments places this provider in the 95th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 31 | $263,239 |
| Invega SustennaPaliperidone Palmitate | 19 | $53,997 |
| Abilify MaintenaAripiprazole | 17 | $47,682 |
| CaplytaLumateperone Tosylate | 20 | $35,692 |
| VraylarCariprazine Hcl | 18 | $26,171 |
| RexultiBrexpiprazole | 13 | $15,912 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $13,139 |
| Duloxetine Hcl | 117 | $1,515 |
| Aripiprazole | 68 | $1,335 |
| Olanzapine OdtOlanzapine | 34 | $1,320 |
| Atomoxetine Hcl | 18 | $1,205 |
| Buspirone Hcl | 70 | $1,196 |
| Bupropion XlBupropion Hcl | 92 | $1,103 |
| Trazodone Hcl | 106 | $1,008 |
| Gabapentin | 116 | $1,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,816 | $263,23931 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,165 | $63,59430 claims |
| Johnson & JohnsonInvega Sustenna | $2,807 | $53,99719 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,001 | $35,69220 claims |
| AbbVieVraylar | $1,104 | $26,17118 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,088 | $13,13912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Tulsa
- Pramila TraxlerTulsa$12K
- Sabrina ConleyTulsa$10K
- la Maria FolksTulsa$10K
- Emily MooreTulsa$9K
- Caroline LeithnerTulsa$7K
- John StanfordTulsa$5K
- Rebekah MackeyTulsa$5K
- Kari MurphyTulsa$5K
- Jordan GillinghamTulsa$5K
- Jennifer AycockTulsa$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.